Zhao Linfang, Cao Xiuzhu, Liu Chang, Wang Jie, Jin Xianghong, Zeng Xufen, Li Xiangyun, Zhuang Yiyu
Department of Nursing, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China.
Wenzhou Medical University, Wenzhou, China.
BMJ Open. 2025 Aug 31;15(8):e093180. doi: 10.1136/bmjopen-2024-093180.
Midline catheters (MCs) longer than 15 cm are increasingly used for intravenous therapy. However, a consensus on the safe administration of irritating infusates (pH <5 or >9, osmolality >900 mOsm/L) is lacking. The current guidelines do not specify how the catheter tip position (axillary vein of the chest wall or subclavian vein) modulates the complication risks. This study investigates the relationship between the tip location, irritant drug properties and vascular injury.
A multicentre, prospective study involving patients receiving irritating infusates via MCs across 12 Chinese hospitals (stratified random sampling of 12 provinces) will be conducted. Preinsertion ultrasound will assess the vascular anatomy, with postinsertion X-ray confirming the tip position. The primary outcome, intima injury, will be assessed through weekly ultrasound evaluations until catheter removal. Secondary outcomes include phlebitis, thrombosis, occlusion and infection. Associations among tip position, drug physicochemical properties, dwell time and complications will be analysed using multivariable logistic and Cox regression analyses.
The study is approved by the Ethics Committee of the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine (#20240096; 20/02/2024). Results will be disseminated through peer-reviewed publication and international conferences.
NCT06454552; Pre-results.
长度超过15厘米的中线导管(MCs)越来越多地用于静脉治疗。然而,对于刺激性输注液(pH<5或>9,渗透压>900mOsm/L)的安全给药缺乏共识。当前指南未明确导管尖端位置(胸壁腋静脉或锁骨下静脉)如何调节并发症风险。本研究调查尖端位置、刺激性药物特性与血管损伤之间的关系。
将在中国12家医院(12个省份分层随机抽样)开展一项多中心前瞻性研究,纳入通过MCs接受刺激性输注液的患者。置管前超声将评估血管解剖结构,置管后X线确认尖端位置。主要结局,即内膜损伤,将通过每周一次的超声评估直至导管拔除来评估。次要结局包括静脉炎、血栓形成、堵塞和感染。将使用多变量逻辑回归和Cox回归分析来分析尖端位置、药物理化性质、留置时间和并发症之间的关联。
本研究已获浙江大学医学院附属邵逸夫医院伦理委员会批准(#20240096;2024年2月20日)。研究结果将通过同行评审发表和国际会议进行传播。
NCT06454552;结果未出。